{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:04:39Z","timestamp":1790355879888,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.jneuroim.2014.01.005","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T15:18:45Z","timestamp":1389799125000},"page":"58-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment with atacicept enhances neuronal cell death in a rat model of optic neuritis"],"prefix":"10.1016","volume":"268","author":[{"given":"Benedikt","family":"Kretzschmar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Hein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Moinfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte","family":"K\u00f6nnecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel B.","family":"S\u00e4ttler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Weissert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"B\u00e4hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2014.01.005_bb0005","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and their receptors: structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0010","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/14712590903033919","article-title":"Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis","volume":"9","author":"Bracewell","year":"2009","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0015","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/rheumatology\/keq404","article-title":"Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses","volume":"50","author":"Chang","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0020","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0025","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1002\/art.23047","article-title":"Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial","volume":"56","author":"Dall'Era","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0030","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1523\/JNEUROSCI.23-18-06993.2003","article-title":"Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway","volume":"23","author":"Diem","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0035","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/ar2959","article-title":"B-lymphocyte stimulator\/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin","volume":"12","author":"Dillon","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0040","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1523\/JNEUROSCI.5705-11.2012","article-title":"Preclinical retinal neurodegeneration in a model of multiple sclerosis","volume":"32","author":"Fairless","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0045","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/art.30373","article-title":"Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0050","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0055","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1084\/jem.188.6.1185","article-title":"APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth","volume":"188","author":"Hahne","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1756285610371146","article-title":"Atacicept: targeting B cells in multiple sclerosis","volume":"3","author":"Hartung","year":"2010","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0065","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0070","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1750-3639.2004.tb00047.x","article-title":"Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis","volume":"14","author":"Hobom","year":"2004","journal-title":"Brain Pathol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0075","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0085","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing\u2013remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0255","series-title":"5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis, Amsterdam","article-title":"ATAMS: a randomized trial of the B-cell-targeting agent atacicept in patients with relapsing multiple sclerosis","author":"Kappos","year":"2011"},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0090","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1073\/pnas.97.7.3370","article-title":"Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice","volume":"97","author":"Khare","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.20041674","article-title":"BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma","volume":"201","author":"Krumbholz","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0095","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/brain\/awn077","article-title":"Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity","volume":"131","author":"Krumbholz","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jneuroim.2006.07.006","article-title":"Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness","volume":"180","author":"Link","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0110","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0120","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0125","first-page":"3420","article-title":"Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression","volume":"118","author":"Matsushita","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0130","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0135","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nm1714","article-title":"Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis","volume":"14","author":"Obermeier","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0140","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0145","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jneuroim.2010.01.011","article-title":"Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis","volume":"220","author":"Piazza","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-pathol-011811-132443","article-title":"Pathology of demyelinating diseases","volume":"7","author":"Popescu","year":"2012","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0155","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI3568","article-title":"Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis","volume":"102","author":"Qin","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0160","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.ajpath.2011.01.003","article-title":"Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis","volume":"178","author":"Rau","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0165","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-065X.2011.01067.x","article-title":"Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease","volume":"244","author":"Rickert","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jneuroim.2007.10.021","article-title":"Strain-specific susceptibility for neurodegeneration in a rat model of autoimmune optic neuritis","volume":"193","author":"S\u00e4ttler","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0175","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0180","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","article-title":"Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis","volume":"14","author":"Serafini","year":"2004","journal-title":"Brain Pathol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0185","series-title":"5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis, Amsterdam","article-title":"ATON: results from a randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis","author":"Sergott","year":"2011"},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0190","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","article-title":"Immunology of multiple sclerosis","volume":"23","author":"Sospedra","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0195","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4049\/jimmunol.163.1.40","article-title":"Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the \u201cresistant\u201d Brown Norway rat: disease susceptibility is determined by MHC and MHC-linked effects on the B cell response","volume":"163","author":"Stefferl","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0200","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1750-3639.1998.tb00194.x","article-title":"Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology","volume":"8","author":"Storch","year":"1998","journal-title":"Brain Pathol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0205","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.smim.2006.04.004","article-title":"BAFF, APRIL and human B cell disorders","volume":"18","author":"Tangye","year":"2006","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0210","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jneuroim.2004.03.017","article-title":"Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis","volume":"152","author":"Thangarajh","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0215","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-3083.2007.01921.x","article-title":"The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis","volume":"65","author":"Thangarajh","year":"2007","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0250","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","volume":"53","author":"The Lenercept Multiple Sclerosis Study Group The University of British Columbia MS\/MRI Analysis Group","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0225","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/1352458510380416","article-title":"Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population","volume":"16","author":"Vaknin-Dembinsky","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0230","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0235","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/art.30372","article-title":"Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial","volume":"63","author":"van Vollenhoven","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0240","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1084\/jem.163.1.41","article-title":"Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis","volume":"163","author":"Walsh","year":"1986","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2014.01.005_bb0245","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1172\/JCI3022","article-title":"MHC haplotype-dependent regulation of MOG-induced EAE in rats","volume":"102","author":"Weissert","year":"1998","journal-title":"J. Clin. Invest."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572814000083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572814000083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:22:02Z","timestamp":1759047722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572814000083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":49,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0165572814000083"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2014.01.005","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with atacicept enhances neuronal cell death in a rat model of optic neuritis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2014.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}